Study on Using Biomarkers to Predict Treatment Response in Patients with Recurrent or Metastatic Triple Negative Breast Cancer

Inclusion Criteria

• Diagnosed with invasive triple negative breast cancer, confirmed by specific medical tests.
• Radiation therapy is needed for the cancer that has come back or spread, and is considered standard care.
• Age 18 or older.
• The tumor to be treated must be measurable by standard medical criteria.
• Willing to have a tumor biopsy before starting treatment.
• Expected to live more than 6 months.
• In good overall health, with a performance status score between 0 and 2.
• Any previous chemotherapy is allowed, including treatments with platinum-based drugs.
• Previous treatments with approved or experimental drugs are allowed, but must be stopped at least 14 days before the study biopsy.
• Women who can become pregnant must use effective birth control.
• Able to understand and sign a consent form.
• Have adequate organ and bone marrow function, as shown by specific blood tests within 14 days before starting the study.

Exclusion Criteria

• Tumors that cannot be measured by standard criteria, such as very small lesions or certain types of cancer spread.
• Brain metastases that need radiation, as these cannot be biopsied and may affect life expectancy.
• Unable to safely obtain a tumor biopsy.
• Finished chemotherapy less than 7 days before starting the study.
• Finished previous radiation therapy less than 7 days before starting the study.
• Expected to live less than 6 months.
• Have other serious illnesses or medical conditions that could affect participation.
• Kidney problems that make cisplatin treatment unsafe.
• Women must not be pregnant or breastfeeding, and must not become pregnant during the study. A negative pregnancy test is required for women who can become pregnant.
• Have another active cancer, unless it is a non-threatening type or was treated more than 2 years ago and has not returned.